LAT-8881 is under clinical development by Lateral Pharma and currently in Phase I for Radiculopathy. According to GlobalData, Phase I drugs for Radiculopathy does not have sufficient historical data to build an indication benchmark PTSR for Phase I. GlobalData uses proprietary data and analytics to create drugs-specific PTSR and LoA in the LAT-8881 LoA Report. Buy the report here.
GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.
LAT-8881 is under development for the treatment of migraine. The drug candidate is administered through oral and intravenous route. The drug candidate acts on Growth Hormone Receptor (GHR).
It was also under development for obesity, cachexia, sarcopenia, HIV wasting syndrome, neuromuscular disorders, muscular dystrophy, achondroplasia, osteoporosis, joint disease, neuropathic pain including post herpetic neuralgia (PHN) and diabetic peripheral neuropathy (DPN), osteoarthritis, lumbar radicular pain, other chronic painful diseases and cartilage repair.
Lateral Pharma overview
Lateral Pharma is a biotechnology company that develops drugs for the treatment of osteoarthritis; and painfull chronic and associated diseases. The company is re-purposing its lead product LAT8881, which is a small amino acid peptide modelled on the C-terminus segment of human growth hormone (hGH). It is investigating LAT8881 in phase 2a, and phase 2b for the treatment of osteoarthritis and various chronic diseases. The company’s LAT8881 has been evaluated using conventional acute and chronic repeat-dose studies in animals. It also has comprehensive preclinical efficacy data capabilities for various disease models, including osteoarthritis. Lateral Pharma is headquartered in Melbourne, Victoria, Australia.
For a complete picture of LAT-8881’s drug-specific PTSR and LoA scores, buy the report here.